| Diabetes Mellitus, Non-Insulin-Dependent
Ozempic vs Trijardy XR
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Ozempic vs Trijardy Xr with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrijardy Xr has a higher rate of injection site reactions vs Ozempic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trijardy Xr but not Ozempic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ozempic
Trijardy Xr
At A Glance
SC injection
Once weekly
GLP-1 receptor agonist
Oral
Daily
SGLT2i / DPP-4i / biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; escalate to 1 mg then 2 mg based on glycemic control (max 2 mg once weekly).
Chronic Kidney Diseases Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; maintenance dose is 1 mg once weekly.
Diabetes Mellitus, Non-Insulin-Dependent Individualize starting dose based on current regimen; maximum 25 mg empagliflozin / 5 mg linagliptin / 2,000 mg metformin HCl once daily; take orally once daily with morning meal, swallow whole. Not recommended for initiation if eGFR <45 mL/min/1.73 m2; contraindicated if eGFR <30 mL/min/1.73 m2.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- Serious hypersensitivity reaction to semaglutide or any excipient in Ozempic
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, linagliptin, metformin HCl, or any excipient (anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred)
Adverse Reactions
Most common (>=5%) Nausea, vomiting, diarrhea, abdominal pain, constipation
Serious Risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration
Postmarketing Ileus, intestinal obstruction, severe constipation, fecal impaction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholecystectomy, dysesthesia, headache, pulmonary aspiration, acute kidney injury, alopecia
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, gastroenteritis
Serious Lactic acidosis, diabetic ketoacidosis, pancreatitis, volume depletion, genitourinary infections (urosepsis, pyelonephritis, Fournier's gangrene, genital mycotic infections), hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis (including fatal), mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria, cholestatic and hepatocellular liver injury
Pharmacology
Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in gastric emptying; prolonged half-life is achieved through albumin binding, which reduces renal clearance and protects against metabolic degradation.
TRIJARDY XR combines three complementary mechanisms: empagliflozin (SGLT2 inhibitor) reduces renal glucose reabsorption and increases urinary glucose excretion; linagliptin (DPP-4 inhibitor) increases active incretin hormones (GLP-1, GIP) to stimulate glucose-dependent insulin release and reduce glucagon; and metformin HCl (biguanide) decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ozempic
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Trijardy Xr
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (11/12)
UnitedHealthcare
Ozempic
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Trijardy Xr
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Ozempic
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Trijardy Xr
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Ozempic Savings Program - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Trijardy Xr.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OzempicView full Ozempic profile
Trijardy XrView full Trijardy Xr profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.